Biosimilars giant Celltrion plans to almost quadruple its current portfolio of six products to 22 by the year 2030, targeting the potential to grow its revenue by at least fivefold by the beginning of the next decade, the Korean firm told the recent annual J.P. Morgan Healthcare Conference under its ‘From Pioneer to Innovator’ business presentation.
In the wake of its presentation, Celltrion announced the launch in the US of an 80mg dose of its 100mg/ml high concentration version of its Yuflyma (adalimumab-aaty)